JPMorgan sees high potential in Morphosys : vimarsana.com

U.S. bank JPMorgan is giving antibody specialist Morphosys plenty of advance praise months before the crucial data readout on its cancer drug pelabresib. More likely than failure is that the trial... | June 16, 2023

Related Keywords

United States , Americans , James Gordon , Constellation Pharmaceuticals , Morphosys Ag Stock Exchange , News , Information , Press Release , Tank , Jpmorgan , Us , Diving , Ntibody , Specialist , Morphosys , Plenty , F , Advance , Raise , Months , Before , The , Crucial , Data , Readout , N , Its , Dancer , Drug , More , Likely , Han , Failure , Hat , He Mor De0006632003 ,